ENTA Latest Press Releases

-- November 4, 2026 --

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 7:00 AM

-- October 28, 2026 --

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership Business Wire 7:00 AM

-- October 26, 2026 --

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) Business Wire 7:00 AM

-- October 13, 2026 --

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek 2026 Business Wire 7:00 AM

-- September 1, 2026 --

Enanta Pharmaceuticals to Participate in September Investor Conferences Business Wire 7:00 AM

-- August 10, 2026 --

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 Business Wire 4:01 PM

-- June 23, 2026 --

Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Business Wire 5:10 AM

-- June 18, 2026 --

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Business Wire 7:00 AM

Market Data Delayed 15 Minutes